High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration
- Jeanna M. Wheeler†1,
- Pamela J. McMillan†1, 2, 3,
- Michele Hawk4,
- Michiyo Iba4,
- Linda Robinson1,
- George J. Xu4,
- Beth A. Dombroski4,
- Doori Jeong4,
- Marc A. Dichter5,
- Halvor Juul5,
- Elaine Loomis1,
- Murray Raskind2, 3,
- James B. Leverenz6,
- John Q. Trojanowski4,
- Virginia M.Y. Lee4,
- Gerard D. Schellenberg4Email author and
- Brian C. Kraemer1, 3, 7Email author
© Wheeler et al.; licensee BioMed Central. 2015
Received: 1 May 2015
Accepted: 4 May 2015
Published: 4 June 2015
Accumulation of insoluble conformationally altered hyperphosphorylated tau occurs as part of the pathogenic process in Alzheimer’s disease (AD) and other tauopathies. In most AD subjects, wild-type (WT) tau aggregates and accumulates in neurofibrillary tangles and dystrophic neurites in the brain; however, in some familial tauopathy disorders, mutations in the gene encoding tau cause disease.
We generated a mouse model, Tau4RTg2652, that expresses high levels of normal human tau in neurons resulting in the early stages of tau pathology. In this model, over expression of WT human tau drives pre-tangle pathology in young mice resulting in behavioral deficits. These changes occur at a relatively young age and recapitulate early pre-tangle stages of tau pathology associated with AD and mild cognitive impairment. Several features distinguish the Tau4RTg2652 model of tauopathy from previously described tau transgenic mice. Unlike other mouse models where behavioral and neuropathologic changes are induced by transgenic tau harboring MAPT mutations pathogenic for frontotemporal lobar degeneration (FTLD), the mice described here express the normal tau sequence.
Features of Tau4RTg2652 mice distinguishing them from other established wild type tau overexpressing mice include very early phenotypic manifestations, non-progressive tau pathology, abundant pre-tangle and phosphorylated tau, sparse oligomeric tau species, undetectable fibrillar tau pathology, stability of tau transgene copy number/expression, and normal lifespan. These results suggest that Tau4RTg2652 animals may facilitate studies of tauopathy target engagement where WT tau is driving tauopathy phenotypes.
KeywordsTau Aggregation Hyperphosphorylation Tauopathy
The microtubule binding protein tau can aggregate to form pathological lesions in a variety of dementia disorders including Alzheimer’s disease (AD), frontotemporal lobar degeneration (FTLD), Pick’s disease, corticobasal degeneration, progressive supranuclear palsy, and agyrophilic grain disease. Collectively, neurodegenerative diseases with pathological tau aggregates are called tauopathies. The unifying features of these disorders are tau pathology, neurodegeneration, and an overlapping suite of neurological features including abnormal cognitive function and/or motor disturbance. While mutations in human MAPT, the gene encoding tau, promote tau aggregation and drive a subset of familial FTLD with underlying tau neuropathology, the vast majority of tauopathy cases do not have MAPT mutations and exhibit aggregation of wildtype (WT) tau.
In AD, WT human tau forms the pathological tau species contributing to neuronal dysfunction and neurodegeneration. Significant efforts have explored the relationship between abnormal tau and disease. For instance, previous studies demonstrated that pathological tau, not amyloid deposition, correlates with the cognitive decline seen in AD , and neurofibrillary degeneration coincides with neuronal loss in AD . Previous work suggested that accumulation of pre-tangle conformations of tau drive progression in AD [3, 4]. However, the exact nature of the toxic species of pathological tau remains a topic of ongoing debate [5–8].
To model sporadic tauopathy we overexpressed the most abundant isoform of WT human tau (1N4R) to provoke pathological changes associated with tauopathy. We generated a new mouse model with abundant overexpression of a normal human tau cDNA sequence that exhibits abundant pre-tangle tau neuropathology accompanied by behavioral abnormalities. While many mouse models of tauopathy have been generated, ours is distinguished by the robustness, rapid onset, and relative stability of the phenotype over time. In particular, the model may have utility for studies of tau transmission as reported by Clavaguera et al  as well as for pre-clinical studies where the ability to assess target engagement at early time points preceding neurofibrillary degeneration is desirable, thus avoiding the time and cost involved in characterizing aged mice.
Materials and methods
MC1 and Alz50 (provided by Peter Davies, Albert Einstein College) are conformation specific mouse monoclonal antibodies that recognize amino acids 7–9 and 313–322 (MC1)  or amino acids 5–15 and 312–322 (Alz50)  of tau and are specific for pathological tau. AT8 (Thermo Scientific, Rockford, IL) is a phosphorylation-dependent mouse monoclonal antibody that recognizes PHF-tau phosphorylated on dual sites Ser202 and Thr205. Other antibodies used in this study that recognize phosphorylated epitopes of tau include AT180 (pThr231; Thermo Scientific), AT270 (pThr181; Innogenetics), and PHF1 (pSer396/pSer404; provided by Peter Davies) . Antibody TOC1 (tau oligomeric complex 1), which selectively labels tau dimers and oligomers, but does not label filaments  was kindly provided by Lester Binder (Michigan State University). Rabbit polyclonal 17025 is a pan-tau antibody recognizing total mouse and human tau raised against full length recombinant tau . SMI31 (Covance, Princeton, N.J.) is a mouse monoclonal antibody that reacts with phosphorylated neurofilament H. The anti-actin mouse monoclonal antibody was obtained from the developmental studies hybridoma bank (dshb.biology.uiowa.edu).
Construction of Transgenic mice
[B6.Cg-Tg(Thy1-MAPT*)2652Gds]. The cDNA encoding the most abundant brain isoform (1N4R) of tau was cloned into the unique XHO I site in a mouse neuron specific expression vector, pThy1.2 . Transgenic (Tg) mice were generated by pronuclear microinjection of the Thy1.2::Tau (1N4R) transgene at the University of Washington Nathan Shock Center Transgenic Animal Model Core (Warren Ladiges, PI). Founders were identified by PCR analysis of tail biopsies as described below. Founder mice were intercrossed with C57BL/6J mice to establish lines. The 2652 line was the focus of characterization due to its high level tau expression and robust phenotype. Mice from the Tau4RTg2652 line used in these studies were backcrossed 6–9 generations (incipient congenic) with the C57BL/6J strain. This mouse strain has been deposited with the Mutant Mouse Regional Resource Centers (MMRRC) and is available under the stock number MMRRC:036717 and the strain name of B6.Cg-Tg(Thy1-MAPT*)2652Gds.
Mice were genotyped using DNA prepared from tail clips from live mice. The presence of the Thy1.2::Tau (1N4R) transgene was detected by PCR analysis using primers yielding a 316 bp product for hemizygous Tg mice and no product for WT animals: cDNA trunc-F, AAGATCGGCTCCACTGAGAA; cDNA trunc-R, GGACGTGGGTGATATTGTCC.
Copy Number analysis
A custom TaqMan® copy number assay was designed by Applied Biosystems® (Assay #MAPT_CCRR9BJ). Primers are within exon 9 of MAPT: Forward primer sequence ACCCAAGTCGCCGTCTTC; reverse primer sequence CCGATCTTGGACTTGACATTCTTCA; Reporter sequence: CAGACAGCCCCCGTGCCCA. The TaqMan® Copy Number Reference Assay, Mouse Tert (part # 4458368) was used for an endogenous control. DNA was extracted from mouse tail samples using DNeasy ™ Blood and Tissue Kit (Qiagen). DNA was quantitated using the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific), and DNA samples were diluted in water to a concentration of 1 ng/μL (to provide 4ng of DNA/reaction). This is less than the manufacturer’s recommended 5 ng/μ L, because of the exceptionally high copy number of the target DNA. TaqMan® Universal PCR Master Mix (Applied Biosystems) was used, in a 96 well plate format, according to the supplier’s protocol for TaqMan® Copy Number Assays; with the exception that primers for the reference assay (Tert) were not placed in the same reaction well as those for Exon 9, the target sequence. Primers failed to amplify Tert when duplexed in the same reaction with primers for the target, likely due to the overabundance of the target sequence relative to the reference sequence. Samples were run in quadruplicate. DNA from a single mouse from a different Tg mouse line [B6.Cg-Mapttm1HndTg(MAPT*)1Gds] was used as a calibrator sample for all assay plates. This mouse line has a low copy number of the human MAPT transgene. Reactions were run on a 7900HT Fast Real-Time PCR System instrument, using the amplification program: 50 °C for 2 min, 95 °C for 10 min, 95 °C for 15 s and 60 °C for 60 s (the last 2 steps repeated 40 times). Generation of standard curves showed that both Tert and MAPT PCR reactions approached 100 % efficiency and were within the linear range using 4 ng of DNA from Tau4RTg2652 mice. Results were analyzed using a CT threshold of 0.2. Because reference and target amplification reactions were performed in different wells, the comparative CT method (∆∆CT) of analysis was used to calculate copy number. In order to obtain an estimation of the absolute copy number of the MAPT cDNA transgene, the ∆ CT between Tert and MAPT reactions was calculated.
All mice were bred and housed at the University of Pennsylvania (Penn) animal facility, and all experiments were approved by the IACUC committee. Mice were housed on a 12:12 light cycle in static microisolators cages, with rodent chow and water available ad libitum. Nestlets (Animal Specialties and Provisions, Quakertown, PA) were added to cages for environmental enrichment in accordance with Penn IACUC mouse care guidelines. All behavioral experiments were conducted during the light phase. Subjects were male and female Tau4RTg2652 animals and their non-Tg littermates. Two separate groups of animals were tested at each of three ages, to eliminate the potential effects of repeated testing. The group sizes were: 3 month group A, 14 Tg and 11 WT; 3 month group B, 12 Tg and 12 WT; 6 month group A, 9 Tg and 11 WT; 6 month group B, 10 Tg and 10 WT; 11 month group A, 7 Tg and 8 WT.
Open field testing was conducted in a 16 × 16 inch square clear plastic arena. All animals were moved into the testing room 30–40 min prior to start of testing. The arena was cleaned with 70% ethanol between animals. Total activity, vertical rearing, and activity in the center of the arena were measured for 10 min using a San Diego Instruments Photobeam Activity System.
The Barnes maze (San Diego Instruments) is a circular white plastic platform 36 inches in diameter with 20 holes around the perimeter. Nineteen holes were occluded with shallow, off-target boxes and one hole leading to a target escape box. Latency to enter the escape box was recorded. Placards with unique monochromatic patterns (vertical lines, horizontal lines, large circles, etc.) were placed around the room to be used as landmarks to find the escape box. The placards were approximately 12" by 14" and were placed at various heights. In addition to these placards a stuffed frog, a tether ball, and a car license plate were also suspended in various areas of the room. The light level on the platform was 375 lux. Mice are placed in a box in the center of the maze for 30 s at the beginning of each trial, so the direction each mouse faces at the trial start is random. When the start box is removed, each animal has a maximum of 2 min to locate the escape box. If the animal locates the hole, it is allowed to shelter there for 1 min before being returned to the home cage. If the animal fails the task, it is gently guided to the escape box by the investigator and allowed to shelter there for 1 min. All animals were moved into the testing room 30–40 min prior to start of testing, and the maze was cleaned with 70% ethanol between animals. Training trials were conducted twice daily for four consecutive days.
Two tests of grip strength were used: ability to hang from an inverted wire grid, and ability to grip a wire bar when pulled by the tail. For the inverted grid test, animals were placed onto a standard wire cage top and encouraged to grip it by gently shaking it. Then the wire top was slowly inverted and suspended approximately 30cm over a padded surface. The amount of time each animal was able to grip the wire grid was recorded, up to a maximum of 2 min. Each animal received three trials on the same day, with a minimum of 30 min rest between trials. Data presented are the average of the three trials for each animal. The T-bar pull-test was performed using a IITC Life Science Grip Strength Meter (Woodland Hills, CA) force gauge with a metal T-bar attached. Animals were held by the tail and allowed to grip the T-bar with forelimbs only, then gently pulled away from the grid to measure maximum grip strength. Each animal received five trials on the same day, with approximately 20 min rest between trials. Data are the average of the five trials for each animal.
Rotorod testing was conducted using an accelerating UGO Basile Rota Rod. The rod surface is covered with ridged plastic, located 16cm above the floor. All mice were transferred to the testing room 30–40 min prior to the start of testing, and were tested on four consecutive days. On the first three days, all mice received three training trials separated by approximately 35 min rest time. For all training trials, mice were placed onto a slowly moving rotorod (3 RPM). Once all mice in a testing group were on the rotorod, the apparatus was accelerated up to 16.75 RPM over 2 min. On the fourth day, mice also received three trials (45–50 min of rest between trials), but the rod was accelerated up to 39 RPM over 5.5 min to test maximum motor coordination abilities.
Statistical analysis was performed using Statistica (StatSoft). For all measures, sex and testing group were included as factors in the ANOVA. If either sex or group did not have a significant effect on a particular measure, then the analysis was repeated without that factor. For repeated measures (rotorod and Barnes testing), ANOVA was followed up with planned comparisons of the two genotypes on each testing day.
Homozygous 4RTauTg3652 mice were anesthetized with isofluorane and implanted bilaterally with electrodes—one with bilateral skull screw electrodes and two with one skull screw and contralateral depth electrodes in the cortex and hippocampus. Following recovery mice were placed in recording cages for 24/7 video EEG recording for 4 to 13 days. EEG was filtered (high pass 0.1 Hz, low pass 600 Hz) and digitized at 2000 Hz.
We conducted a sequential extraction of tau protein using buffers of increasing solubilizing strength as previously described . Mouse brains from three non-Tg and nine Tau4RTg2652 mice at varying ages were isolated and snap frozen on liquid nitrogen prior to extraction. Mouse brain hemispheres were homogenized in high salt re-assembly buffer (RAB-High Salt [0.1 M MES, 1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 0.5 mM PMSF, 0.1 % protease inhibitor cocktail, pH 7.0]) and ultra-centrifuged at 50,000x gravity yielding the soluble fraction (supernatant) and an insoluble pellet. Next, myelin was floated by resuspending the pellet in RAB/1M sucrose and centrifuging as above. To extract detergent soluble tau, the RAB insoluble material was re-extracted with an ionic and non-ionic detergent containing RIPA buffer [50 mM Tris, 150 mM NaCl, 1% NP40, 5mM EDTA, 0.5 % DOC, 0.1 % SDS, 0.5 mM PMSF, 0.1 % protease inhibitor cocktail, pH 8.0] and centrifuged as above yielding abnormal tau in the supernatant. Finally, the detergent insoluble pellet was re-extracted with 70 % Formic Acid (FA) to solubilize detergent insoluble tau. Total protein fractions containing ~15 ug of protein per lane were boiled 5 min and loaded onto 10 % pre-cast SDS-PAGE gels (Biorad, Hercules, CA). Subsequent RIPA and FA extracted fractions were normalized according to the levels of total protein in the total fraction. For semi-quantitative immunoblotting, we detected mouse and human tau using the pan tau antibody 17025 at a dilution of 1:3000 as described previously  and anti-actin antibody at 1:1000 (DSHB). Densitometry measurements were performed using Adobe Photoshop to determine total tau levels in non-Tg and Tg mice.
Immunohistochemistry and histological stains
Tg mice at three months (n = 9) and 1 year (n = 12) were examined by immunohistochemistry with antibodies MC1 and AT8. A subset of these brains was also immunostained with Alz50, AT180, AT270, PHF-1, TOC1 and SMI31. Mice were anesthetized and fixed by transcardial perfusion with 4% paraformaldehyde. Brains and spinal cords were removed and paraffin embedded for sectioning. Coronal sections from the forebrain, hippocampus, and brainstem were cut at 10 μm thickness and stored at 4 °C until use. Sections were deparaffinized and rehydrated through alcohols, and an antigen retrieval step consisting of heat pretreatment by microwave in citrate buffer was used when necessary. Sections were treated for endogenous peroxidases with 3 % hydrogen peroxide in PBS (pH 7.4), blocked in 5 % non-fat milk in PBS, and incubated with primary antibody overnight at 4°C followed by biotinylated secondary antibody for 45 min at room temperature. Finally, sections were incubated in an avidin-biotin complex (Vector’s Vectastain Elite ABC kit, Burlingame, CA) and the reaction product was visualized with 0.05 % diaminobenzidine (DAB)/0.01% hydrogen peroxide in PBS. Negative controls with secondary antibody alone did not immunostain tissue sections (data not shown). The presence of neurofibrillary tangles (NFTs) was assessed by Gallyas silver and Thioflavin-S staining using standard methods . Bielschowsky silver stain was utilized to assess axonal pathology .
Photomicrography and figure preparation
Photomicrographs were taken with a digital camera and imported into Adobe Photoshop for mounting. To optimize visualization of staining, photomicrographs were modified when necessary by adjusting brightness and contrast.
Accumulation of pathological tau
To measure total tau levels, whole mouse brains from 3 month old, 6 month old, 12 month old, and 20 month old mice were homogenized and immunoblotted with a pan-tau specific antibody, demonstrating total human tau levels ~12 fold greater than normal endogenous mouse tau in non-Tg mice (Fig. 1). We homogenized brain hemispheres from non-Tg mice and the aged Tau4RTg2652 animals in RAB, a high salt buffer, yielding the soluble tau fraction. We observe consistently high levels of total tau among all Tg animals in this fraction. We re-extracted material insoluble in RAB with RIPA, an ionic and non-ionic detergent containing buffer yielding the detergent soluble fraction. Subsequently, we recovered detergent insoluble material by extraction with formic acid. Non-Tg animals exhibit nearly all tau in the soluble fraction (RAB) with no detergent insoluble tau detected. In contrast the Tau4RTg2652 mice exhibit marked but highly variable accumulation of aggregated tau in the detergent soluble (RIPA) and detergent insoluble (FA) fractions.
Additional phospho-tau epitopes and NFT analysis in Tau4RTg2652 mice
Characterization of behavioral deficits
At weaning Tau4RTg2652 animals weigh significantly less than their non-Tg littermates (supplemental data, Additional file 2: Figure S2). There is a significant main effect of genotype on body weight at 3, 6, and 11 months of age (p < 0.001 at all ages in both sexes). Examination of muscle tissue from Tg mice revealed atrophic fibers indicative of neurogenic muscle atrophy, whereas no such muscle wasting was observed in non-Tg littermates (supplemental data, Additional file 2: Figure S2). This atrophy likely accounts for the weight and strength differences between the genotypes.
We used two measures to assess muscle strength in Tau4RTg2652 animals. In the grid hang test, which measures the amount of time an animal can hang onto an inverted wire cage top, we found that Tau4RTg2652 animals hang onto the inverted grid for less time at all three ages tested (main effect of genotype p < 0.001 at all ages, supplemental data). At 3 months of age, there was also a significant main effect of sex on grid hang times (p = 0.017). However, both male and female Tg animals had lower grid hang times than their non-Tg littermates (p < 0.001 for both sexes). The second measure of muscle strength uses a force meter to assess grip strength directly (supplemental data). At all three ages tested, Tau4RTg2652 animals had weaker forelimb grip strength (main effect of genotype p < 0.001 at all ages). As for the grid hang test, we found a significant main effect of sex on forelimb grip strength at 3 months of age (p = 0.006), but comparisons showed that both male (p < 0.001) and female (p = 0.001) Tg animals had significantly lower grip strength than non-Tg animals.
Tau4RTg2652 animals displayed somewhat lower levels of motor coordination as measured by ability to walk on an accelerating rotorod (Fig. 6d). There was a main effect of genotype on rotorod times in 3 month old animals (p = 0.002), and planned comparisons revealed significant genotype effects on days 1, 2, and 4 of testing. In contrast to the results for open field activity at 3 months, there were no observed sex differences in rotorod abilities at 3 months. Six month old Tg animals also had decreased ability to perform on the rotorod (main effect of genotype p < 0.001), with significant effects on all days of testing. Similarly, at 11 months Tg animals performed more poorly than non-Tg (main effect of genotype p < 0.001), and planned comparisons showed significant differences on days 1, 2, and 4 of testing.
We also measured transgene copy number in the hemizygous animals used for behavioral assays. There was no correlation between transgene copy number and severity of behavioral deficits for any of the tests performed at any age (see Additional file 1: Figure S1). However, there is a dose dependency of the transgenic phenotype as animals homozygous for the Tau4RTg2652 transgene exhibit reduced body weight, exaggerated motor abnormalities, reduced fertility, and premature death in addition to the neuropathological changes documented for the hemizygous animals. A number of the homozygous mice were also noted to have seizure-like behaviors. In order to confirm that these behavioral events were electrographic seizures, EEGs were performed on a small subset of the Tau4RTg2652 mice. The EEGs documented both interictal spike discharges and recurrent seizures in Tau4RTg2652 mice (Fig. 7b).
We have generated a new mouse model of tauopathy whereby pan-neuronal overexpression of the most abundant WT adult brain isoform of human tau results in the early signs of tauopathy. By 3 months of age Tau4RTg2652 mice exhibit motor and learning deficits accompanied by extensive accumulation of soluble human tau and measurable detergent insoluble aggregated tau species. In particular, Tg mice were found to have weaker muscle strength as early as 3 months of age. They also exhibited decreased motor learning abilities during rotorod training, as well as decreased maximum motor skills on the rotorod. Barnes maze testing indicated that Tg mice have deficits in spatial learning and memory abilities. Neuropathological examination revealed robust accumulation of pre-tangle and hyperphosphorylated tau in the neurons of the cortex, hippocampus, amygdala, brainstem and spinal cord as well as white matter tracts in the striatum, corpus callosum and anterior commissure. Pathological tau was evident both in the axons and somatodendritic compartment of these affected cells. The initial tempo of phosphorylated and misfolded pathological tau accumulation is rapid reaching maximal levels by three months of age, in correspondence with behavioral impairment. However, beyond 3 months there is little evidence of additional progression in tauopathy, but rather persistent maintenance of both behavioral and neuropathological phenotypes. There was no evidence for either focal or widespread neuronal loss, but neuronal cortical dysfunction was clearly evidenced by behavioral abnormalities.
One distinguishing feature of the Tau4RTg2652 model is a relatively high level of tau expression which provokes an early tauopathy-like cascade. Tau undergoes somatodendritic relocalization, becomes hyperphosphorylated and freed from microtubules, and then conformationally altered to adopt the “paperclip fold” as indicated by MC1 immunoreactivity [24, 25]. Interestingly, despite high levels of hyperphosphorylated and pre-tangle tau accumulation there is extremely limited accumulation of oligomeric tau (as detected by TOC1 antibody) . Likewise the model exhibits a complete lack of Gallyas silver or thioflavin S positivity demonstrating a clear absence of tau fibrillization or NFT formation. We attribute the relative lack of progression in behavioral phenotypes after 3 months of age to a dearth of oligomeric or fibrillar tau pathological species. We propose that phospho-tau and/or “paperclip fold” conformations of tau, which occur in abundance in even young Tau4RTg2652, drive cognitive dysfunction.
Other mouse models of tauopathy driven by WT human tau transgenes have been produced previously. The ALZ17  and htau40  lines have several features in common, including the presence of phosphorylated and insoluble tau species in the cortex and spinal cord. Both lines express 1N4R tau under a Thy-1 promoter, similar to Tau4RTg2652. In all three cases, the resulting pathology has an early onset, observable in young adult animals, and exhibiting very slow progression if any at all. Similarly, none of the three lines have neurofibrillary tangles or any significant neurodegeneration even in old age. One important difference between these previously generated tau Tg lines and Tau4RTg2652 mice is the more widespread presence of pathological tau species in Tau4RTg2652 brains, including striatal pathology. In addition, due to the relatively mild reduction of spontaneous locomotor activity in Tau4RTg2652 mice, we can confidently interpret their impairment in the Barnes maze as a cognitive deficit. The ability to assess cognitive abilities provides additional validity and utility to Tau4RTg2652 as a model for use in future preclinical drug studies.
Models that express the 3R isoform of human tau have also been studied. Whereas humans express approximately equal amounts of 3R and 4R tau in the adult brain, adult mice normally only express 4R tau. Ishihara et al. produced Tg mice that express 3R human tau using the PrP promoter . These mice exhibit markers of tau pathology (various phospho-tau epitopes and Alz50) in spinal cord as early as 1 month of age, and milder pathology in cortex by 6 months. In addition there is progressive accumulation of insoluble tau and a more severe motor phenotype than that observed in Tau4RTg2652 mice. Htau mice [28, 29] express all isoforms of human tau, but do not express any mouse 4R tau, thus producing an imbalance of 3R:4R tau. These mice have more developed tau pathology, including the presence of NFT’s and progressive neurodegeneration. Htau mice also have cognitive deficits in the absence of any observable motor dysfunction . Despite the presence of mouse 4R tau and the absence of human 3R tau in Tau4RTg2652 mice, we similarly see cognitive deficits in the absence of severe motor dysfunction. Tau4RTg2652 mice provide the benefit of an early and consistent cognitive deficit starting at 3 months, as opposed to htau mice which are not distinguished from WT at 4 months. Thus Tau4RTg2652 mice may provide an alternative model for examining tau interventions without the need to age animals for extended periods.
The presence of abundant monomeric phospho-tau and pre-tangle tau species combined with the relative lack of oligomeric or fibrillar tau species makes Tau4RTg2652 a valuable model for investigations into the mechanisms of tauopathy progression. Our model does show that gross increase in cytoplasmic tau and conversion to the pre-pathologic form detected by MC1 is insufficient to drive formation of neurofibrillary tangles. Additional unknown factors are needed for the type of aggregation that leads to tangles and neurodegeneration. The lack of disease progression beyond mild cognitive and motor impairment driven by soluble pathological tau species sets the stage for studies in the Tau4RTg2652 model to identify toxic insults promoting tau fibrillization and neurodegeneration. For example, studies of extracellular spreading or seeding of tauopathy ideally require a model where tangle formation does not normally occur, but the subunits of tangles are present (ie pre-tangle tau conformers). Likewise, the model is very well suited to investigations of genetic or environmental insults that may exacerbate tauopathy.
While there have been many different Tg mouse models of tauopathy reported to date (reviewed in ), most of them rely upon FTLD-tau causing mutations to drive tau neuropathology and the associated behavioral phenotypes. In the Tau4RTg2652 model, unique features support its adoption for preclinical studies where tauopathy driven by WT human tau is desirable. Specifically, the Tau4RTg2652 model exhibits a rapid and highly consistent accumulation of pathological tau such that by three months of age high levels of pretangle hyperphosphorylated tau and concomitant behavioral abnormalities are readily observed with statistical significance in small group sizes. Furthermore, low variability in transgene copy number, tau accumulation, neuropathology, and behavioral abnormalities provides experimental advantages not evident in many other Tg mouse models of tauopathy. Thus we favor this model for studies exploring the progression and treatment of WT tau driven tauopathies, which represent the majority of human dementia cases. Given the early onset of phenotypes and low variability, we anticipate use of the Tau4RTg2652 model will provide significant experimental advantage when conducting preclinical therapeutic studies focused on measuring engagement of early pathological tau changes as the therapeutic target.
This work was supported by National Institute on Aging Grants AG17586 to GDS and AG017586 to VMYL. Department of Veterans Affairs Merit Review Grant to BCK, and Veterans Affairs. We thank the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging for supporting mouse transgenics. We thank Leo Anderson, Susan Danner, Andrea Jurkovic, Christian Kramer, and Swetha Narayanan for outstanding technical assistance. We thank Skip Binder and Peter Davies for sharing their tau conformation specific monoclonal antibodies. Tubulin and actin antibodies were provided by the Developmental Studies Hybridoma Bank at the University of Iowa. In addition we thank the Neurobehavior Testing Core at the University of Pennsylvania, for aiding in the design and interpretation of the behavior studies. We thank Angela K. Brice, DVM, PhD, DACVP, staff veterinary pathologist, and JanLee Jensen, DVM, DACVIM, clinical veterinarian with the University of Pennsylvania Laboratory Animal Resources for their help in the investigation and examination of pathology in this mouse model. Finally, we thank Edward Lee MD, PhD for consultation on histopathology and photomicroscopy.
- Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631–639PubMedView ArticleGoogle Scholar
- Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41:17–24. doi:10.1002/ana.410410106 PubMedView ArticleGoogle Scholar
- Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969. doi:10.1097/NEN.0b013e318232a379 PubMedView ArticleGoogle Scholar
- Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP (2007) Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging 28:1–7. doi:10.1016/j.neurobiolaging.2005.11.001 PubMedView ArticleGoogle Scholar
- Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663–672PubMedView ArticleGoogle Scholar
- Buee L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, Fernandez-Gomez F, Caillierez R, Grosjean ME, Begard S et al (2010) From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans 38:967–972. doi:10.1042/BST0380967 PubMedView ArticleGoogle Scholar
- Gotz J, Xia D, Leinenga G, Chew YL, Nicholas H (2013) What Renders TAU Toxic. Frontiers in Neurology 4:72. doi:10.3389/fneur.2013.00072 PubMed CentralPubMedView ArticleGoogle Scholar
- Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2:a006247. doi:10.1101/cshperspect.a006247 PubMed CentralPubMedView ArticleGoogle Scholar
- Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913. doi:10.1038/ncb1901 PubMed CentralPubMedView ArticleGoogle Scholar
- Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21:719–727PubMedView ArticleGoogle Scholar
- Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986) A neuronal antigen in the brains of Alzheimer patients. Science 232:648–650PubMedView ArticleGoogle Scholar
- Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267:564–569PubMedGoogle Scholar
- Ward SM, Himmelstein DS, Lancia JK, Fu Y, Patterson KR, Binder LI (2013) TOC1: characterization of a selective oligomeric tau antibody. J Alzheimers Dis 37:593–602. doi:10.3233/JAD-131235 PubMedGoogle Scholar
- Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751–762PubMedView ArticleGoogle Scholar
- Seki T, Spurr N, Obata F, Goyert S, Goodfellow P, Silver J (1985) The human Thy-1 gene: structure and chromosomal location. Proc Natl Acad Sci U S A 82:6657–6661PubMed CentralPubMedView ArticleGoogle Scholar
- Guthrie CR, Schellenberg GD, Kraemer BC (2009) SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum Mol Genet 18:1825–1838. doi:10.1093/hmg/ddp099 PubMed CentralPubMedView ArticleGoogle Scholar
- Sun AY, Nguyen XV, Bing GY (2002) Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. Journal of Histochemistry & Cytochemistry 50:463–472View ArticleGoogle Scholar
- Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, Amadio S, Bergami A et al (2003) Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422:688–694. doi:10.1038/nature01552 PubMedView ArticleGoogle Scholar
- Ward SM, Himmelstein DS, Lancia JK, Binder LI (2012) Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40:667–671. doi:10.1042/BST20120134 PubMed CentralPubMedView ArticleGoogle Scholar
- Ward SM, Himmelstein DS, Ren Y, Fu Y, Yu XW, Roberts K, Binder LI, Sahara N (2014) TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy. Neurobiol Dis 67:37–48. doi:10.1016/j.nbd.2014.03.002 PubMedView ArticleGoogle Scholar
- Barnes CA (1979) Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. Journal of Comparative and Physiological Psychology 93:74–104PubMedView ArticleGoogle Scholar
- O'Leary TP, Brown RE (2009) Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res 201:120–127. doi:10.1016/j.bbr.2009.01.039 PubMedView ArticleGoogle Scholar
- Takeuchi H, Iba M, Inoue H, Higuchi M, Takao K, Tsukita K, Karatsu Y, Iwamoto Y, Miyakawa T, Suhara T et al (2011) P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS ONE 6:e21050. doi:10.1371/journal.pone.0021050 PubMed CentralPubMedView ArticleGoogle Scholar
- Jeganathan S, vonBergen M, Brutlach H, Steinhoff HJ, Mandelkow E (2006) Global hairpin folding of tau in solution. Biochemistry 45:2283–2293PubMedView ArticleGoogle Scholar
- Kanaan NM, Morfini G, Pigino G, LaPointe NE, Andreadis A, Song Y, Leitman E, Binder LI, Brady ST (2012) Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging 33:826 e815–830. doi:10.1016/j.neurobiolaging.2011.06.006 Google Scholar
- Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM, Trojanowski JQ et al (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 99:469–481PubMedView ArticleGoogle Scholar
- Spittaels K, Vandenhaute C, Vandorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Vanlommel A et al (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. American Journal of Pathology 155:2153–2165PubMed CentralPubMedView ArticleGoogle Scholar
- Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25:5446–5454. doi:10.1523/JNEUROSCI.4637-04 PubMedView ArticleGoogle Scholar
- Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582–590PubMedView ArticleGoogle Scholar
- Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29:10741–10749. doi:10.1523/JNEUROSCI.1065-09.2009 PubMed CentralPubMedView ArticleGoogle Scholar
- Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9:532–544. doi:10.1038/nrn2420 PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.